[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573834":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":63,"collaborators":26,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":26,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":82,"conditions":83,"keywords":26,"overallStatus":55,"whyStopped":26,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Herbarium Laboratorio Botanico Ltda","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants of both sexes, 18 - 70 y","ACTIVE_COMPARATOR","Participants of both sexes, 18 - 70 y, who have recent scars.",[13],"Device: Scar gel comparator",{"label":15,"type":16,"description":17,"interventionNames":18},"Exp.: Participants of both sexes, 18 - 70 y","EXPERIMENTAL","Participants of both sexes, 18 - 70 y, with recent scars",[19],"Device: Scar gel",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Scar gel","Health care product (scar gel)",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Scar gel comparator","Health care product (Scar gel comparator)",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Flávia A. S. Addor","CONTACT","(55) 11 3683-5366","contato@medcinpesquisa.com.br",[38,53],{"facility":39,"status":40,"city":41,"state":42,"zip":26,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Medcin Instituto da Pele Ltda","NOT_YET_RECRUITING","Osasco","São Paulo","Brazil","BR",{"type":46,"coordinates":47},"Point",[48,49],-46.79167,-23.5325,{"lat":49,"lon":48},[52],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"facility":54,"status":55,"city":41,"state":26,"zip":26,"country":43,"countryCode":44,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},"MEDCIN","RECRUITING",{"type":46,"coordinates":57},[48,49],{"lat":49,"lon":48},[60],{"name":61,"role":34,"phone":62,"phoneExt":26,"email":36},"Addor","(55) (11) 3683-5366",{"type":64,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100573834","phase-1-evaluation-of-clinical-perceived-and-instrumental-efficacy-of-a-scar-gel-in-preventing-hypertrophic-scars-100573834",false,"NCT06751433","Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars","Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel Versus Benchmark in Preventing Hypertrophic Scars and Improving Scar Appearance","Inclusion Criteria:\n\n1. Participants of both sexes aged between 18 and 70 years;\n2. Participants with recent scars (\\\u003C30 days);\n3. Participants with phototypes III to VI according to the Fitzpatrick scale;\n4. Agree to follow the trial procedures and attend the center on the days and times determined for evaluations;\n5. Understand, agree to and sign the free and informed consent form.\n6. Types of scars: cesarean section, breast implant or blunt cut injury.\n\nExclusion Criteria:\n\n1. Pregnancy or risk of pregnancy;\n2. History of atopic or allergic reactions to cosmetic products;\n3. Participants who are using topical antibiotics or other skin products on the same area being evaluated;\n4. Immunosuppression due to drugs or active diseases;\n5. Decompensated endocrine diseases;\n6. Relevant clinical history or current evidence of alcohol or other drug abuse;\n7. Known history or suspected intolerance to products in the same category;\n8. Intense sun exposure up to 15 days before the evaluation;\n9. Patients who are using topical antibiotics or other skin products on the same area being evaluated.","ALL","18 Years","70 Years",{"count":76,"type":77},80,"ESTIMATED","INTERVENTIONAL",[80,81],"PHASE1","PHASE2","Evaluation of the safety and topical efficacy of a scar gel after 90 days of continuous use, comparing it to a benchmark for preventing hypertrophic scars and improving appearance, hydration and pigmentation.",[84,85,86,87,88,89],"Acceptability Study","Real-use Conditions","Safety and Efficacy","Topical Administration","Hypertrophic Scars","Keloid Scars","2025-09-09",{"date":92,"type":93},"2025-09-11","ACTUAL",{"date":95,"type":93},"2025-04-03",{"date":97,"type":77},"2025-12",{"name":5,"class":6},2]